In summary, these results suggest FMK protects against HG-induced β-cell dysfunction and against TXNIP expression via ChREBP regulation in pancreatic β-cells, and that FMK be viewed as a potential therapeutic for the treatment of diabetes. Here, MLXIPL is linked to diabetes mellitus.